Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
CAS Registry Number
2266591-83-5
Molecular formula
C662H865F19N231O413P57S6
Molecular weight
20985.24 g/mol
Drug class
Lactate dehydrogenase A (LDHA)-directed small interfering RNA (siRNA)RNA interference therapy
Mechanism of action
A GalNAc-conjugated siRNA is taken up by hepatocytes and directs RNA-induced silencing complex-mediated degradation of LDHA mRNA, reducing hepatic glycolate-to-glyoxylate conversion and lowering oxalate production.
Indications / reported uses
Reduction of urinary oxalate in adults and children aged 2 years and older with primary hyperoxaluria type 1 (PH1) and relatively preserved kidney function (eGFR at least 30 mL/min/1.73 m²) under the US RIVFLOZA indication
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Nedosiran PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Nedosiran Permitted Daily Exposure (PDE) report (the Nedosiran PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Nedosiran Occupational Exposure Limit (OEL) report (the Nedosiran OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.